Angiomax/Angiox (Bivalirudin) Reduced Cardiac Mortality by 44%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty

MedPage Today -- The final report from the HORIZONS-AMI trial revealed an increasing mortality benefit for ST-elevation MI patients treated with bivalirudin (Angiomax) -- compared with those who received unfractionated heparin plus abciximab (ReoPro) or eptifibatide (Integrilin), according to the trial’s lead investigator.